Okamoto syndrome
Okamoto syndrome is a rare genetic disorder characterized by a variety of physical and developmental abnormalities. It was first described by Nobuhiko Okamoto in 1997. The syndrome is also known as Okamoto syndrome 1 and is caused by mutations in the HNRNPK gene.
Clinical Features[edit | edit source]
Individuals with Okamoto syndrome typically present with a range of clinical features, including:
- Intellectual disability
- Distinctive facial features such as a broad forehead, hypertelorism (wide-set eyes), and a short nose with a flat nasal bridge
- Congenital heart defects
- Kidney abnormalities
- Hearing loss
- Growth retardation
- Hypotonia (reduced muscle tone)
Genetics[edit | edit source]
Okamoto syndrome is inherited in an autosomal dominant manner. The condition is caused by mutations in the HNRNPK gene, which is located on chromosome 9. This gene encodes a protein that is involved in various cellular processes, including RNA processing and gene expression.
Diagnosis[edit | edit source]
The diagnosis of Okamoto syndrome is based on clinical evaluation and the identification of characteristic features. Genetic testing can confirm the diagnosis by detecting mutations in the HNRNPK gene. Prenatal diagnosis may be possible if the mutation in the family is known.
Management[edit | edit source]
There is no cure for Okamoto syndrome, and treatment is symptomatic and supportive. Management may include:
- Early intervention programs and special education to address intellectual disability
- Surgical correction of congenital heart defects
- Monitoring and treatment of kidney abnormalities
- Hearing aids or other interventions for hearing loss
- Physical therapy to improve hypotonia
Prognosis[edit | edit source]
The prognosis for individuals with Okamoto syndrome varies depending on the severity of the symptoms and the presence of associated complications. Early diagnosis and intervention can improve the quality of life for affected individuals.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD